Ranking by Regions
United States
Canada
Mexico
Brazil
Chile
Germany
United Kingdom
France
Spain
Netherlands
Sweden
Italy
Switzerland
Poland
Finland
China
Japan
South Korea
Hong Kong
Singapore
Indonesia
India
Malaysia
Taiwan
Thailand
Australia
New Zealand
Israel
Saudi Arabia
Turkey
Russia
South AfricaRanking by categories
As of January 22, 2025, Gilead Sciences (GILD) has a market cap of $116.07 billion USD. According to our data, Gilead Sciences is ranked No.142 in global market value.
| Year | Market Cap | %Change |
|---|---|---|
| Jan 22, 2025 | $116.07 B |
0.83%
|
| Dec 31, 2024 | $115.12 B |
18.68%
|
| Dec 29, 2023 | $97.00 B |
-1.99%
|
| Dec 30, 2022 | $98.97 B |
23.63%
|
| Dec 31, 2021 | $80.05 B |
29.95%
|
| Dec 31, 2020 | $61.60 B |
-6.70%
|
| Dec 31, 2019 | $66.02 B |
7.88%
|
| Dec 31, 2018 | $61.20 B |
-9.92%
|
| Dec 29, 2017 | $67.94 B |
2.96%
|
| Dec 30, 2016 | $65.99 B |
-27.59%
|
| Dec 31, 2015 | $91.14 B |
8.63%
|
| Dec 31, 2014 | $83.90 B |
25.51%
|
| Dec 31, 2013 | $66.84 B |
104.49%
|
| Dec 31, 2012 | $32.69 B |
79.45%
|
| Dec 30, 2011 | $18.21 B |
12.94%
|
| Dec 31, 2010 | $16.13 B |
-16.25%
|
| Dec 31, 2009 | $19.26 B |
-15.39%
|
| Dec 31, 2008 | $22.76 B |
11.15%
|
| Dec 31, 2007 | $20.48 B |
41.72%
|
| Dec 29, 2006 | $14.45 B |
23.51%
|
| Dec 30, 2005 | $11.70 B |
50.24%
|
| Dec 31, 2004 | $7.79 B |
20.08%
|
| Dec 31, 2003 | $6.48 B |
71.41%
|
| Dec 31, 2002 | $3.78 B |
3.47%
|
| Dec 31, 2001 | $3.66 B |
58.48%
|
| Dec 29, 2000 | $2.31 B |
53.23%
|
| Dec 31, 1999 | $1.51 B |
31.81%
|
| Dec 31, 1998 | $1.14 B |
7.35%
|
| Dec 31, 1997 | $1.06 B |
53.00%
|
| Dec 31, 1996 | $0.70 B |
-21.88%
|
| Dec 29, 1995 | $0.89 B |
236.84%
|
| Dec 30, 1994 | $0.26 B |
-20.83%
|
| Dec 31, 1993 | $0.33 B |
-37.66%
|
| Dec 31, 1992 | $0.54 B |
100%
|
| Name | Market Cap | Market cap difference | Regions |
|---|---|---|---|
 Amgen
AMGN
|
$147.53 B |
0.002 M
|
USA
|
 Biogen
BIIB
|
$20.75 B |
0.203 B
|
USA
|
 Bristol-Myers Squibb
BMY
|
$115.86 B |
0.003 M
|
USA
|
 Merck
MRK
|
$242.59 B |
0.007 M
|
USA
|
 Pfizer
PFE
|
$148.34 B |
-0.006 M
|
USA
|
 Johnson & Johnson
JNJ
|
$347.78 B |
-0.005 M
|
USA
|
 AbbVie
ABBV
|
$300.53 B |
0.002 M
|
USA
|
 Regeneron Pharmaceuticals
REGN
|
$75.23 B |
1.245 B
|
USA
|
 Vertex Pharmaceuticals
VRTX
|
$110.70 B |
-0.001 M
|
USA
|
 Eli Lilly
LLY
|
$676.92 B |
0.020 M
|
USA
|
 Novartis
NVS
|
$197.43 B |
0.007 M
|
Switzerland
|
 Sanofi
SNY
|
$128.55 B |
0.003 M
|
France
|
 GlaxoSmithKline
GSK
|
$68.38 B |
0.002 M
|
UK
|
 AstraZeneca
AZN
|
$211.43 B |
0.005 M
|
UK
|
| Market Cap | = | GILD Stock Price | * | GILD Shares Outstanding |
| = | $93.14 | * | 1.25 B | |
| = | $116.07 B |